MegaBanner-Right

MegaBanner-Left

LeaderBoad-Right

LeaderBoard-Left

Home » Industry News » Manufacturing » Manufacturing meds In South Africa

Manufacturing meds In South Africa

The South African government is partnering with U.S.-based pharmaceutical giant Pfizer in a five-year transfer of technology and skills that will allow SA to stop importing an expensive pneumonia vaccine for infants and start manufacturing it at home, Reuters reports.

Pneumonia is the leading infectious cause of death among children worldwide, accounting for 15% of all deaths in children under the age of 5, according to the World Health Organisation. It’s an acute respiratory infection caused by bacteria, fungi or viruses that fills the lungs. It killed 935,000 children under age 5 in 2013, according to Reuters.

Vaccine prices have skyrocketed in the last decade. The South African government pays R184.90 ($13.36 US) for a single dose of imported Prevenar 13. Each infant needs three doses of the pneumonia vaccine.

Pneumonia vaccine accounts for 40% of South Africa’s vaccines budget, Reuters reports.

Pfizer has partnered with South Africa’s Biovac Institute to produce the pneumonia vaccine for infants, a cabinet minister said.

Pfizer, whose top sellers include Lyrica for pain and rheumatoid arthritis treatment Enbrel, ranks No. 3 among about 2,000 publicly traded pharmaceutical and biotech companies around the world, Bloomberg reported.

The South African government owns a 47.5% stake in Biovac, according to Reuters. A five-year partnership, announced at Biovac’s Cape Town manufacturing facility, will include transferring upgraded technology and skills to produce Prevenar 13 vaccine sustainably, said Naledi Pandor, Science and Technology Minister.

Biovac already supplies over 25 million doses of vaccines a year that protect against a range of diseases including tuberculosis and polio.

“There is more that we can do to cut the costs of the (pneumonia) vaccine, and that is to manufacture the vaccine here in Cape Town,” Pandor said at a news conference, Reuters reported.

The goal is that South Africa will no longer be importing the vaccine by 2020, but will instead be producing it, Pandor said. “There won’t be an immediate saving because we will still continue to import … but in the final analysis, when we get to 2020 we shouldn’t be purchasing the vaccine in dollars but as manufactured in South Africa.”


 

 

AFK Insider

 

To enquire about Cape Business News' digital marketing options please contact sales@cbn.co.za

Related articles

RLabs creates a R100-million venture unit to foster township businesses

By Larry Claasen RECONSTRUCTED Living Labs (RLabs), a Cape Town-based NGO, has created a R100-million venture capital fund to support emerging innovative businesses that will...

How top companies ensure sustainable water and savings

Water Sustainability has become good business - how do companies get it right? WHEN a drought forced the Tennessee Valley Authority to reduce its hydropower...

MUST READ

Over R100-billion to be invested in data centres in South Africa 

By Larry Claasen Amazon Web Services (AWS) plans to invest R46-billion in Cape Town by 2029. THE setting up of hyperscale data centres in South Africa...

RECOMMENDED

Cape Business News
Follow us on Social Media